MHRA Authorises Redemplo as a New FCS Treatment in England and Wales

The UK Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for plozasiran, marketed as Redemplo, as a treatment option for adults with familial chylomicronaemia syndrome to reduce triglycerides.